In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

Pfizer’s PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. Image Source: Zacks ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...

As you probably know, Pfizer is a giant among pharmaceutical stocks, recently sporting a market value of $154 billion. It's been around since before the Civil War, as it was launched in 1849 in ...

Pfizer Inc. research and ratings by Barron's. View PFE revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.